NEW ORLEANS — In this Healio Video Perspective from the AAO meeting, Raymond Douglas, MD, PhD, discusses results of a clinical trial examining adherence to teprotumumab and reasons for nonadherence in patients with thyroid eye disease.
Uncategorized
VIDEO: 90% of patients in clinical trial adhere to teprotumumab